相关实验视频

Updated: Jan 10, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

最近在针对性膜蛋白降解技术的进展,基于aptamers治疗疾病的技术

Xiaolong Li¹, Yanni Wang¹, Tingting He¹

¹Chongqing Key Laboratory of Medicinal Chemistry and Molecular Pharmacology, Chongqing University of Technology, Chongqing 400054, China. fyqiao@cqut.edu.cn.

Biomaterials science

|November 28, 2025

概括

基于aptamer的向蛋白降解 (TPD) 提供了一种新的方法来消除引起疾病的蛋白质,包括以前无法治疗的膜蛋白. 这种创新策略克服了传统治疗方法的局限性.

科学领域:

生物化学生物化学
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

向性蛋白质降解 (TPD) 是一种治疗策略,可以选择性降解致病蛋白质,解决药物耐药性问题.
许多致病性蛋白质,特别是膜蛋白质,是传统治疗方法无法获得的,限制了治疗选择.

研究的目的:

审查基于aptamer的向蛋白质降解 (TPD) 技术的最新进展.
突出阿普坦体在克服针对与疾病相关的膜蛋白的挑战方面的潜力.

主要方法:

通过体外查选择的aptamers被利用,因为它们对与疾病相关的膜蛋白具有高度亲和力和特异性.
基于aptamer的TPD技术将膜蛋白输送到细胞中进行降解.

主要成果:

基于Aptamer的TPD有效地向并降解与疾病相关的膜蛋白,包括癌症,心血管疾病和炎症中的膜蛋白.
这项技术在向以前"无药"的蛋白质方面取得了重大进展.

结论:

基于aptamer的TPD代表了疾病治疗策略的重大进步.
这种方法扩大了可治疗疾病的范围,使以前无法获得的致病蛋白质能够降解.

更多相关视频

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins

Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins

Published on: August 9, 2019

相关概念视频

Regulated Protein Degradation

Regulated Protein Degradation

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

The Proteasome

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...

The Proteasome

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...